BioStock Article: Further steps in Aptahem's phase I study

At the end of December 2022, biotech company Aptahem announced the completion of cohort 1 in healthy volunteers for the phase I study with the sepsis candidate Apta-1. Now, the second dose cohort is also ready and approved by the Dutch Ethics Committee and dose cohort three has started. BioStock talked to CEO Mikael Lindstam to learn more.

Read the full interview with Aptahem´s CEO Mikael Lindstam at biostock.se:

https://www.biostock.se/en/2023/02/further-steps-in-aptahems-phase-i-study/

For further information:

Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com

About Aptahem

Aptahem AB (APTA) is a clinical stage biotechnology company that develops aptamer-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company’s lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.

Tags: